Phil Palmer
Cambridge, UK
Bio
Updated 07/23/26 · Provided by member · VerifiedCo-founder of safely.bio, building customer verification for the biotech industry to reduce AI-enabled catastrophic biorisks. Previously, I've spent 7+ years working across: - Academia — PhD at Cambridge, where I computationally designed the first single-protein vaccine to protect against all three known highly pathogenic coronaviruses; visiting researcher at MIT, building metagenomics pipelines for biothreat detection in Kevin Esvelt's group. - Industry — one of the first ~10 employees at Lifebit Biotech, through a $7.5M Series A. - Policy — developing safeguards for AI-enabled biological risks at the Centre for Long-Term Resilience (CLTR) and the Nuclear Threat Initiative (NTI).
Links
Updated 07/08/26 · Provided by member · VerifiedProjects
Grants
Updated 07/23/26 · By grantmaking.aiNo grants recorded.